A. Horsley

Consortium‐Based Patient and Public Involvement and Engagement for Long COVID Research: A Pirit‐Focused Impact Evaluation of the PHOSP‐COVID Study

Linzy Houchen‐Wolloff, Rebecca Pritchard, Krisnah Poinasamy, Kate Holmes et autres

BACKGROUND: At the start of the coronavirus disease-2019 (COVID-19) pandemic in early 2020, the long-term outcomes for survivors of COVID-19 were unknown. The PHOSP-COVID cohort study was set up at scale and pace in Spring 2020 to determine the short- to long-term …

gb (code pays fourni par la source)

567 Prevalence and predictors of hidden obesity and hidden fat free mass depletion in adults with cystic fibrosis at a large regional centre in the North West of England

Laura Kinsey, A. Horsley, AM Jones

120 Changes in sweat chloride concentrations following CFTR modulator treatment and association with antibiotic usage in adolescents and adults with cystic fibrosis

Sivagurunathan Sutharsan, Marcus Alexander Mall, B. Ramsey, Elizabeth D. Tullis et autres

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Kaja Abbas et autres

BACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital …

WS03.03Capturing a cough. Results of a pilot study to assess the utility of cough plates for microbiological surveillance in CF

Christopher B. Fordyce, P. Farrell, A.M. Jones, A. Horsley

gb (code pays fourni par la source)

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Amr E. Abbas, Fatima H. Abbas, Jonathan Raihan Abbas et autres

BACKGROUND: Molnupiravir and nirmatrelvir-ritonavir are oral antivirals that have shown efficacy in preventing disease progression in outpatients with COVID-19. We aimed to evaluate these treatments for patients hospitalised with COVID-19 pneumonia, for whom data on these antivirals are scarce. METHODS: The RECOVERY …

CF Tummy Tracker: A Cystic Fibrosis–Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden

Rebecca J Calthorpe, Hisham A. Saumtally, Laura Howells, N. Goodchild et autres

Objective: To develop a cystic fibrosis (CF)-specific patient-reported outcome measure (PROM) to measure the daily burden of gastrointestinal symptoms for people with cystic fibrosis (pwCF) aged 12 years and older and address the lack of validated outcome measures for gastrointestinal symptoms in …

gb, ch (code pays fourni par la source)

S82 Persistently raised serum amyloid A in never-hospitalised Long-COVID patients without association with lung or coagulation abnormalities: the EXPLAIN study (hyperpolarised xenon magnetic resonance pulmonary imaging in patients with long-COVID)

KL Ng, Laura C. Saunders, Guilhem J. Collier, James T. Grist et autres

Introduction Persistent breathlessness is commonly reported in Long-COVID, even by those who were never hospitalised for COVID-19 (NHLC). The multicentre, prospective EXPLAIN study explored whether NHLC breathlessness was associated with abnormalities in multinuclear MRI assessment of gas transfer using hyperpolarised xenon gas …

gb (code pays fourni par la source)

S2 Evaluation of lung transplant function and detection of CLAD using 129Xe-MRI and LCI

Madeleine Driskel, H Marshall, Alberto M. Biancardi, Lloyd R. Smith et autres

Introduction Outcomes after LTx are limited by development of Chronic Lung Allograft Dysfunction (CLAD), defined spirometrically as an FEV1 <80% best post-transplant (ISHLT criteria). Lung clearance Index (LCI) is sensitive to early small airway disease. Hyperpolarised-MRI using 129Xe (HPMRI) enables functional imaging …

gb (code pays fourni par la source)

P261 Presentation and recovery from pulmonary exacerbations in cystic fibrosis and comparison of those with and without CFTR modulators

H Siy-Yap, V. Musgrave, Evelyn Looi, L.E. Wadsworth et autres

Objectives Recent falls in CF admissions have been attributed to reduced exacerbations (PEx) in patients on CFTR modulators. We aimed to understand how these have affected the presentation and course of PEx. Methods Admission data were collected over 9m from July 2023 …

gb (code pays fourni par la source)

639 CF Tummy Tracker: adherence to a daily patient-reported outcome measure to track gastrointestinal burden in cystic fibrosis

Hishaam Saumtally, Rebecca J Calthorpe, N. Goodchild, Kerry-Lee Watson et autres

WS09.01 Impact of long-term elexacaftor/tezacaftor/ivacaftor therapy on lung infection microbiota in adults with cystic fibrosis

Helen Gavillet, L. Hatfield, Thomas W V Daniels, A. Horsley et autres

gb (code pays fourni par la source)